198 related articles for article (PubMed ID: 38242121)
1. Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome.
Liu D; Yehia L; Dhawan A; Ni Y; Eng C
Cell Rep Med; 2024 Feb; 5(2):101384. PubMed ID: 38242121
[TBL] [Abstract][Full Text] [Related]
2. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
3. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.
Ngeow J; Stanuch K; Mester JL; Barnholtz-Sloan JS; Eng C
J Clin Oncol; 2014 Jun; 32(17):1818-24. PubMed ID: 24778394
[TBL] [Abstract][Full Text] [Related]
4. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F;
J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
Brewer T; Yehia L; Bazeley P; Eng C
Am J Hum Genet; 2022 Aug; 109(8):1520-1533. PubMed ID: 35931053
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications for Germline PTEN Spectrum Disorders.
Ngeow J; Sesock K; Eng C
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):503-517. PubMed ID: 28476234
[TBL] [Abstract][Full Text] [Related]
7. Novel dermatological and skeletal features associated with PTEN variant in PTEN hamartoma tumor syndrome.
Comeau D; Allain V; Maillet-Lebel N; Ben Amor M
Eur J Med Genet; 2023 Aug; 66(8):104798. PubMed ID: 37307869
[TBL] [Abstract][Full Text] [Related]
8. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
10. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
Bennett KL; Mester J; Eng C
JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
[TBL] [Abstract][Full Text] [Related]
11. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
12. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
13. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
14. PTEN hamartoma tumor syndromes in childhood: description of two cases and a proposal for follow-up protocol.
Piccione M; Fragapane T; Antona V; Giachino D; Cupido F; Corsello G
Am J Med Genet A; 2013 Nov; 161A(11):2902-8. PubMed ID: 24123798
[TBL] [Abstract][Full Text] [Related]
15. Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.
Ngeow J; He X; Mester JL; Lei J; Romigh T; Orloff MS; Milas M; Eng C
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2320-7. PubMed ID: 23066114
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants.
Yehia L; Plitt G; Tushar AM; Joo J; Burke CA; Campbell SC; Heiden K; Jin J; Macaron C; Michener CM; Pederson HJ; Radhakrishnan K; Shin J; Tamburro J; Patil S; Eng C
JAMA Netw Open; 2023 Apr; 6(4):e239705. PubMed ID: 37093598
[TBL] [Abstract][Full Text] [Related]
17. PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review.
Rahmatinejad Z; Goshayeshi L; Bergquist R; Goshayeshi L; Golabpour A; Hoseini B
Diagn Pathol; 2023 Apr; 18(1):43. PubMed ID: 37016356
[TBL] [Abstract][Full Text] [Related]
18. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.
Pilarski R; Burt R; Kohlman W; Pho L; Shannon KM; Swisher E
J Natl Cancer Inst; 2013 Nov; 105(21):1607-16. PubMed ID: 24136893
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of
Liu A; Borges PM; Tay YS; Thompson LDR; Kong MX; Lai J
Anticancer Res; 2022 Mar; 42(3):1481-1485. PubMed ID: 35220242
[TBL] [Abstract][Full Text] [Related]
20. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
